SUPPLEMENTATION WITH 2:1 RATIO OF N-6:N-3 POLYUNSATURATED FATTY ACID IMPROVES LIVER STEATOSIS AND SERUM CYTOKINE LEVELS IN YOUNG OBESE BALINESE WOMEN: A RANDOMIZED CLINICAL TRIAL
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i12.20851Keywords:
young obese women, 2, 1 n-6, n-3 PUFA ratio, cytokines, liver steatosisAbstract
Â
 Objectives: In addition to the rise in obesity prevalence globally, morbidity due to nonalcoholic fatty liver disease is increasing. Primary modalities for preventing and managing this problem include dietary modification and improved physical activities. A daily diet with a low n-6:n-3 polyunsaturated fatty acid (PUFA) ratio is suspected to contribute to ameliorating liver steatosis (LS). The present study was conducted to elucidate the effects of an n-6:n-3 PUFA ratio of 2:1 in alleviating LS.
Methods: Twenty-four young obese women with LS were recruited from Denpasar, Bali, Indonesia. They were randomly allocated to an intervention or control group. Both groups were given linoleic acid:α-linolenic acid at ratios of 2035:970 and 240:100 g, respectively, for 12 weeks. Baseline and end-line data were obtained. All patients were advised to maintain their daily energy intake no more than 1500 kcal and to perform structured physical exercises once a week.
Results: The intervention significantly decreased the body fat (body mass index, p=0.040; triglyceride, p=0.008) and serum tumor necrosis factor-α (TNF-α) levels (p=0.002) and increased serum interleukin-10 (IL-10) levels (p=0.004). The severity of LS was reduced through the intervention (odds ratio=0.064; 95% confidence interval=0.013-0.310; p=0.001).
Conclusion: An increased intake of 2:1 n-6:n-3 PUFA ratio alleviated LS, decreased body fat composition and serum TNF-α levels, and increased serum IL-10 levels.
Downloads
References
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010;51(2):679-89.
Mirza MS. Obesity, visceral fat, and NAFLD: Querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol 2011;2011:592404.
Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014;20(7):1712-23.
Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol 2015;5(2):147-58.
Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanism involved in NAFLD progression. J Mol Med 2009;87:679-95.
Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 2007;65:S57-63.
de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol 2008;48:S104-12.
More JB. Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome. Conference on ‘Over- and undernutrition: Challenges and approaches’. Proc Nutr Soc 2010;69:211-20.
Obika M, Noguchi H. Diagnosis and evaluation of non alcoholic fatty liver disease. Exp Diabetes Res 2012;2012:145754.
Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, et al. Effect of weight loss on some serum cytokines in human obesity: Increase in IL-10 after weight loss. J Nutr Biochem 2008;19(6):371-5.
Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006;83(2):461S-5.
Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013;4:93.
Elizondo A, Araya J, Rodrigo R, Signorini C, Sgherri C, Comporti M, et al. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol Res 2008;41(1):59-68.
Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: Mechanistic insights. Adv Nutr 2011;2(4):304-16.
Pocock SJ. Clinical Trials-A Practical Approach. Chichester: John Wiley and Sons; 2008.
USDA. National Nutrient Database for Standard Reference, SR-27. Baltimore: National Agricultural Library; 2011.
McDonald BE. Canola oil: Nutritional Properties. Canada: Canola Council of Canada; 2005. Available from: http://www.canola–Council.org/pdf/nutritionalprop.pdf. [Last cited on 2015 Sep 09].
Dauqan EM, Sani HA, Abdullah A, Kasim ZM. Fatty acids composition of four different vegetable oils (red palm olein, palm olein, corn oil and coconut oil) by gas chromatography. In: The 2nd International Conference on Chemistry and Chemical Engineering, IPCBEE. Singapore: IAGSIT Press; 2014.
Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fuji K, Nakajima T, et al. The severity of ultra-sonographic findings in non-alcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708-15.
Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, et al. Review article: The diagnosis of non-alcoholic fatty liver disease-availability and accuracy of noninvasive methods. Aliment Pharmacol Ther 2013;37:392-400.
Kirkwood BR, Sterne JA. Essential Medical Statistic. 2nd ed. Singapore: Blackwell Science; 2003.
Yang LG, Song ZX, Yin H, Wang YY, Shu GF, Lu HX, et al. Low n-6/n-3 PUFA ratio improves lipid metabolism, inflammation, oxidative stress and endothelial function in rats using plant oils as n-3 fatty acid source. Lipids 2016;51(1):49-59.
Heerwagen MJ, Stewart MS, de la Houssaye BA, Janssen RC, Friedman JE. Transgenic increase in N-3/n-6 fatty acid ratio reduces maternal obesity-associated inflammation and limits adverse developmental programming in mice. PLoS One 2013;8(6):e67791.
Depner CM, Philbrick KA, Jump DB. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr2/2 mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 2013;143:315-23.
Lionetti L, Mollica MP, Sica R, Donizzetti I, Gifuni G, Pignalosa A, et al. Differential effects of high-fish oil and high-lard diets on cells and cytokines involved in the inflammatory process in rat insulin-sensitive tissues. Int J Mol Sci 2014;15(2):3040-63.
Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012;56(4):944-51.
Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Veck M, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 2004;39(12):1177-85.
Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial. Arch Dis Child 2011;96(4):350-3.
Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013;23(11):1066-70.
Sanders TA, Lewis F, Slaughter S, Griffin BA, Griffin M, Davies I, et al. Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of alpha-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45-70 y: The OPTILIP study. Am J Clin Nutr 2006;84(3):513-22.
Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, Ma J. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16(7):1364-70.
Wu CC, Huang MY, Kapoor R, Chen CH, Huang YS. Metabolism of omega-6 polyunsaturated fatty acids in women with dysmenorrhea. Asia Pac J Clin Nutr 2008;17 Suppl 1:216-9.
Wang X, Lin H, Gu Y. Multiple roles of dihomo-?-linolenic acid against proliferation diseases. Lipids Health Dis 2012;11:25.
Burdge GC, Wootton SA. Convertion of alpha linolenic acid to ecosapentanoic, docosapenta-enoic and docosa-hexanoic acids in young women. Br J Nutr 2002;88:411-20.
MejÃa-Barradas CM, Del-RÃo-Navarro BE, DomÃnguez-López A, Campos-RodrÃguez R, MartÃnez-GodÃnez MD, Rojas-Hernández S, et al. The consumption of n-3 polyunsaturated fatty acids differentially modulates gene expression of peroxisome proliferator-activated receptor alpha and gamma and hypoxia-inducible factor 1 alpha in subcutaneous adipose tissue of obese adolescents. Endocrine 2014;45(1):98-105.
Wójcik C, Lohe K, Kuang C, Xiao Y, Jouni Z, Poels E. Modulation of adipocyte differentiation by omega-3 polyunsaturated fatty acids involves the ubiquitin-proteasome system. J Cell Mol Med 2014;18(4):590-9.
Yahagi N, Shimano H, Hasty AH, Amemiya-Kudo M, Okazaki H, Tamura Y, et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 1999;274(50):35840-4.
Xu J, Nakamura MT, Cho HP, Clarke SD. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem 1999;274(33):23577-83.
Koenig G, Seneff S. Gamma-glutamyltransferase: A predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers 2015;2015:818570.
Konuma K, Itoh M, Suganami T, Kanai S, Nakagawa N, Sakai T, et al. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One 2015;10(3):e0121528.
Abdel-Sttar AR, Khalaf MM, Aboyoussef AM, Abosaif AA. Ameliorative effect of hesperidin on carbon tetrachloride induced liver fibrosis in rats. Int J Pharm Pharm Sci 2017;9(7):45-51.
Ahmed AH, Salem AM, Mohamed MR, Shahat AA, Khalil WK, Mohamed SH. Experimental evidences for the promising therapeutic role of Vitis vinifera seed extract against nonalcoholic steatohepatitis. Int J Pharm Pharm Sci 2015;7(2):417-24.
Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012;18(41):5839-47.
Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: Implications for obesity and diabetes. Clin Chem 2013;59(4):617-28.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
